USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: BIOTEK, INC.
City: WOBURN
State: MA
Zip+4: 01801
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (781) 938-0938

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,334,459.00 64
SBIR Phase II $14,324,339.00 28

Award List:

DEVELOPMENT OF A ONCE-DAILY CONTRACEPTIVE SKIN PATCH

Award Year / Program / Phase: 1984 / SBIR / Phase I
Agency: HHS
Principal Investigator: E.s. Nuwayser , President
Award Amount: $49,999.00

DEVELOPMENT OF A ONCE-DAILY CONTRACEPTIVE SKIN PATCH

Award Year / Program / Phase: 1986 / SBIR / Phase II
Agency: HHS
Principal Investigator: E.s. Nuwayser , President
Award Amount: $500,000.00
Abstract:
The overall objective of the research application is to demonstrate the potential of the dermapatch drug delivery system developed by biotek for the transdermal delivery of therapeutic agents. the specific objective is to illustrate this potential by testing in living animals a dermapatch for the… More

ANTIMICROBIAL WOUND DRESSING

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: Dr Michael H Gay
Award Amount: $50,000.00

SUSTAINED-RELEASE NALTREXONE MICROCAPSULES

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael h gay phd
Award Amount: $50,000.00
Abstract:
The objective of this project is to develop sustained-action, injectable, biodegradable, naltrexone microcapsules to maintain plasma levels at 2 ng/ml for at least 1 month. phase i support is sought for a 6-month period to conduct preliminary feasibility studies. during phase i, naltrexone… More

MICROENCAPSULATION OF UNSTABLE CHEMICALS FOR RODENT FEED

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: E s nuwayser
Award Amount: $49,000.00
Abstract:
The overall objective of the project is to develop microencapsulation procedures and formulations for stabilizing the properties of chemicals that are unstable under normal environmental conditions. the stable microcapsules will be mixed with rodent feed, and the chronic toxicity of the chemicals… More

SUSTAINED-RELEASE FLUORIDE DENTIFRICE

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie s nuwayser phd
Award Amount: $50,000.00
Abstract:
The overall objective of the 6-month project is to develop asustained-release fluoride dentifrice formulation based on microcapsules with a duration of 12 to 24 hours. in phase i, sodium fluoride microcapsules will be prepared and characterized for naf content, geometry, and fluoride-release… More

TRANSDERMAL NICOTINE-AN AID TO SMOKING CESSATION

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Es Nuwayser Phd
Award Amount: $50,000.00

SUSTAINED-ACTION NALMEFENE

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Es Nuwayser Phd
Award Amount: $50,000.00

ANTIMICROBIAL WOUND DRESSING

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: Dr Michael H Gay
Award Amount: $480,000.00
Abstract:
Combat wounds are characterized by a high incidence of infection. topical application of broad spectrum antimicrobial agents by sustained release system can provide therapeutic levels for a prolonged period with minimal systemic toxicity. biotek is developing a wound dressing based on this concept.… More

DEVELOPMENT OF TRANSDERMAL ANTIHISTAMINE DELIVERY SYSTEM

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The overall objective of the project is to develop a transdermal dosage form of the h(1)-blocker carbinoxamine for 24-hour control of allergic rhinitis. in phase i the feasibility of such dosage will be tested. in vitro transdermal penetration experiments with nude mouse skins, as well as in vivo… More

ONE WEEK SUSTAINED RELEASE METHADONE MICROCAPSULES

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00

TRANSDERMAL NICOTINE-AN AID TO SMOKING CESSATION

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator: Es Nuwayser Phd
Award Amount: $476,900.00
Abstract:
Nicotine substitution or maintenance has been shown to be aneffective aid for ceasing smoking. the overall goal of this program is to develop a transdermal nicotine delivery system as an aid to cessation of smoking based on biotek, inc.'s dermapatch concept and system for preparing sustained-release… More

SUSTAINED-ACTION NALMEFENE

Award Year / Program / Phase: 1989 / SBIR / Phase II
Agency: HHS
Principal Investigator: Es Nuwayser Phd
Award Amount: $492,300.00
Abstract:
Nalmefene has been shown to be an effective pharmacological intervention for protecting postaddicts from re-addiction. with this modality, in contrast to methadone, the patient isfree of opioids. the overall objective of this program during the next 3 years is to develop a sustained-action… More

HEAT-ACTIVATED MICROPARTICLE DRUG DELIVERY SYSTEMS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $50,000.00
Abstract:
The overall objective of the project is to develop heat-activated microparticle drug delivery systems for delivery of chemotherapeutic agents that could be used in conjunction with therapeutic hyperthermia or hyperthermia plus radiation. during phase i, microparticles will be prepared from… More

SUSTAINED-RELEASE MICROCAPSULES FOR MEGALOBLASTIC ANEMIA

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $49,927.00
Abstract:
The objective of this project is to develop a biodegradable injectable microcapsule system for sustained release of vitamin b12 for maintenance therapy of patients with megaloblastic anemia. after a single intramuscular or subcutaneous administration, the dosage form will release the required… More

ONE WEEK SUSTAINED RELEASE METHADONE MICROCAPSULES

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $489,927.00
Abstract:
The overall objective of the project is to develop sustained action injectable biodegradable l-methadone microcapsules which will maintain plasma levels of 200 ng/ml for one week. phase i sbir support is sought for a six month period to conduct preliminary feasibility studies. during phase i… More

SUSTAINED-ACTION BUPRENORPHINE

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael H Gay
Award Amount: $49,289.00

SUSTAINED-ACTION BUPRENORPHINE

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator: Michael H Gay
Award Amount: $489,791.00
Abstract:
Buprenorphine has been shown to suppress heroin use by addicts, and studies indicate that it may be a useful treatment for opioid dependence. this partial agonist-antagonist combines the advantages of both methadone and naltrexone, and buprenorphine was preferred bypostaddicts over methadone and… More

AN ESTROGEN-PROGESTIN PATCH FOR ESTROGEN REPLACEMENT

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, Elie S , Principal Investigator
Award Amount: $47,824.00

SUPPOSITORIES FOR RAPID ANTI-EPILEPTIC DIAZEPAM DELIVERY

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: E.s. Nuwayser , Principal Investigator
Award Amount: $49,982.00

DEVELOPMENT AND TESTING OF NEW SPERMICIDE SUPPOSITORY

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, Elie S , Principal Investigator
Award Amount: $50,000.00

DEVELOPMENT OF BIOPORE BIODEGRADABLE DELIVERY SYSTEM FOR BONE-INDUCTIVE PROTEINS AND GROWTH FACTORS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: E.s. Nuwayser, Ph.d.
Award Amount: $49,974.00
Abstract:
Craniofacial injuries, either congenital or acquired, are a major cause of disfigurement and loss of function. they account for a significant fraction of wartime casualties and of civilian injuries from moving vehicle accidents. congenital craniofacial defects occur in cleft-palate and… More

TRANSDERMAL TERBUTALINE FOR THE TREATMENT OF ASTHMA

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: A G Tsuk
Award Amount: $49,993.00
Abstract:
Asthma is a costly and widespread breathing disorder prone to strike children. advances in treatment have led to beta-2 adrenergic drugs, such as terbutaline hemisulfate (tbs), which provide relief with few of the side effects, such as tachycardia, of earlier drugs. unfortunately, tbs has poor… More

IMPROVED DOSED DELIVERY OF HORMONES

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S Nuwayser
Award Amount: $49,976.00
Abstract:
A rapidly increasing number of hormones and bioactive peptides are becoming available to medical researchers. these drugs cannot be orally administered, so it is important to investigate their pharmacological effects as depot injections, first in animals and eventually in humans. the cost of peptide… More

A 30-DAY SUSTAINED RELEASE INJECTION OF CLONAZEPAM

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S Nuwayser
Award Amount: $49,918.00
Abstract:
Epilepsy is a family of recurrent seizure disorders afflicting 1-2 million people in the u.s. alone. although the antiepileptic drug development program of ninds has effectively fostered the development of new anticonvulsant drugs, there remain significant limitations in methods available for… More

N/A

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S Nuwayser
Award Amount: $49,997.00

PRODUCTION OF POLYCLONAL ANTIBODIES IN RABBITS

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency / Branch: DOD / ARMY
Principal Investigator: E.s. Nuwayser, Ph.d.
Award Amount: $49,903.00

SUPPOSITORIES FOR RAPID ANTI-EPILEPTIC DIAZEPAM DELIVERY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: E.s. Nuwayser , Principal Investigator
Award Amount: $491,795.00
Abstract:
The contractor shall prepare experimental suppositories, test them in rabbits, make indicated modifications, and demonstrate that these suppositories have practical potential for rapid treatment of convulsions in human beings. the contractor shall prepare experimental suppositories, test them in… More

AN ESTROGEN-PROGESTIN PATCH FOR ESTROGEN REPLACEMENT

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nuwayser, Elie S , Principal Investigator
Award Amount: $371,183.00
Abstract:
The objective of this research application is to utilize biotek's transdermal drug delivery system for the development of a sustained transdermal delivery system for estradiol and levonorgestrel for use in estrogen replacement therapy. conditions for estradiol and levonorgestrel transdermal delivery… More

DEVELOPMENT AND TESTING OF NEW SPERMICIDE SUPPOSITORY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Nuwayser, Elie S , Principal Investigator
Award Amount: $359,057.00
Abstract:
We will evaluate the duration of efficacy of a bioerodible contraceptive spermicide suppository in animals. we seek to optimize the formulation to release spermicide over a period of 12-16 hours in the limited fluid environment of the vagina. the old and new formulation will be screened in rabbits… More

PRODUCTION OF POLYCLONAL ANTIBODIES IN RABBITS

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency / Branch: DOD / ARMY
Principal Investigator: E.s. Nuwayser, Ph.d.
Award Amount: $252,556.00
Abstract:
Cholinesterases are widely distributed throughout the body. they hydrolyze acetylcholine (ach), a compound which serves also as the neurohumoral agent in peripheral junction transmission. cholinesterases are known to be crucial for cholinergic neurotransmission and occur at high concentrations in… More

Development of a Naltrexone Microcapsule Injection

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $49,973.00

Injectable Microcapsule for Estrogen Replacement Therapy

Award Year / Program / Phase: 1993 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $49,984.00

Hydroformed Microspheres as New Injectable Drug Vehicle

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry Nichols
Award Amount: $79,500.00
Abstract:
We have developed a new hydroforming process for making sustained release injectablebiodegradable microsphere and microcapsule well suited for delivery of water soluble drugs such aspeptides and proteins. The process incorporates drug into hydroformed microspheres made of sparinglysoluble calcium… More

Buprenorphine For Transdermal Analgesia

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry Nichols
Award Amount: $80,225.00
Abstract:
We will demonstrate the practical feasibility of transdermal analgesic therapy based onbuprenorphine, a potent opioid already used intravenously and intramuscularly for the relief of moderateto severe pain. Preliminary in vitro experiments have confirmed that buprenorphine can pass throughhuman skin… More

Development of a Naltrexone Microcapsule Injection

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $602,870.00
Abstract:
We will develop clinically useful naltrexone sustained release microcapsules for use in reducing re-addiction among recently withdrawn abusers. Naltrexone is an opiate antagonist which physiologically blocks the narcotic reinforcement mechanism. The microcapsules are targeted to contain more than… More

Injectable Microcapsule for Estrogen Replacement Therapy

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $508,083.00
Abstract:
Estrogen replacement therapy has been found to reduce the risk of cardiovascular disease and osteoporosis associated with decreased estrogen levels following menopause. It is the purpose of Phase I to demonstrate the feasibility of an injectable, fully biodegradable microcapsule form of estradiol… More

Biodegradable Antibiotic Beads for Osteomyletis

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie Nuwayser
Award Amount: $79,941.00
Abstract:
Deep infection following open fractures or bone surgery are a challenging orthopedic problem. The ugentamicin-impregnated PMMA cement or beads has become a successful part of the management of osteomchronic post-fracture infections, but these materials have disadvantages, such as the need for a… More

Biodegradable Bone Matrix for Peptide Delivery

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie Nuwayser
Award Amount: $99,959.00
Abstract:
There is need for a convenient biodegradable bone substitute to support soft tissue and stimulate bWe will combine its unique BIOPORE material with the recently characterized osteogenic growth peptidthis objective. BIOPORE is a porous biodegradable material developed by BIOTEK. OGP is a… More

Biodegradable Polylactide-Co Glycolide Medical Cements

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry Nichols
Award Amount: $99,990.00
Abstract:
Osteomyelitis is a serious orthopedic problem, and its prevention or treatment using systemic antibcomplications and is often unsuccessful. The use of polymethylmethacrylate beads or bone cement to dto bone sites does reduce the incidence of post- operative bone infections, but these non-porous… More

BIODEGRADABLE LEVONORGESTREL CONTRACEPTIVE IMPLANTS

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,554.00

N/A

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Elie S Nuwayser
Award Amount: $739,172.00

NEW METHOD FOR TREATING SLEEP DISORDERS IN THE AGED

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,999.00

BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,981.00

TIN FREE CATALYST FOR BIODEGRADABLE POLYESTERS

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,987.00

NEW BIODEGRADABLE POLYMERS BASED ON MANDELIC ACID

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $99,988.00

SBIR PHASE I--MEDICATIONS DEVELOPMEN-DEPOT NALMEFENE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, Elie
Award Amount: $99,983.00

ONE MONTH INJECTION FOR OSTEOPOROSIS

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, Elie S
Award Amount: $99,998.00

SBIR PHASE I--MEDICAATIONS DEVELOPMENT--DOSE RESPONSE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, Elie
Award Amount: $99,964.00

BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES

Award Year / Program / Phase: 1998 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $663,634.00

ABUSE RESISTANT TRANSDERMAL BUPRENORPHINE FOR OPIATE

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nichols, Larry
Award Amount: $99,964.00

A RAPID ACTING LORAZEPAM GEL FOR EPILEPTIC SEIZURES

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, E S
Award Amount: $99,980.00

A ONE WEEK SUSTAINED RELEASE OF CLONAZEPAM

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Nuwayser, E S
Award Amount: $99,942.00

BIODEGRADABLE GUIDES FOR PERIPHERAL NERVE REGENERATION

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kitchell, Judith P
Award Amount: $99,979.00

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $547,458.00

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase II
Agency: HHS
Principal Investigator: Larry Nichols
Award Amount: $661,418.00

ONE YEAR ESTROGEN/PROGESTIN IMPLANT

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,910.00
Abstract:
Not Available The importance of a low-drag, efficient fuel injection systemfor scramjet combusion cannot be overstated. Fuel injection and mixing have been identified by the Air Force Hypersonic Technology Office as significant technological challneges, which must be addressed as a prerequisite… More

EPISODIC TRANSDERMAL DELIVERY FROM MELTABLE VEHICLES

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,979.00
Abstract:
Not Available The ISE Research Hybrid-Electric Aircraft Loader (HEAL) project is aimed at developing an improved technology for powering large aircraft loaders. The HEAL integrated hybrid-electric power system will combine a central electrical power system with a small onboard generator, powered by… More

EVALUATION OF A 24 HOUR MICROBICIDE VAGINAL SUPPOSITORY

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $188,792.00
Abstract:
Not Available With the increase threat of chemical and biological warfare (CBW), each and every shelter should have all the features to protect the troops from CBW. The one and only reason that the troops are not protected from CBW unconditionally as a doctrine, is cost. The high cost resulting… More

TRANSDERMAL PROSTAGLANDIN E1 TO TREAT MALE IMPOTENCE

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,849.00
Abstract:
Not Available The Phase 1 project examines the concept of low-cost and low RCS GPS protection capability for advanced rotary wing aircraft using an L1/L2 antenna retrofit. The project examines the tail stabilizer GPS antenna installation of the Comanche RAH-66 and forward antenna location for… More

TRANSDERMAL LEVONORGESTREL FOR EMERGENCY CONTRACEPTION

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,962.00
Abstract:
Not Available The Navy has many tactical and operational missions that require equipment powered by lightweight, high output internal combustion engines, 5 to 150 BHP. Navy inventory of engine powered equipment in this size range is predominantly gasoline fueled. Department of Defense (DoD) has… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,965.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $165,167.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $343,077.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,850.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $99,975.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Es Nuwayser
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Es Nuwayser
Award Amount: $297,742.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Es Nuwayser
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Es Nuwayser
Award Amount: $268,678.00

Transdermal Levonorgestrel for Emergency Contraception

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $234,530.00
Abstract:
DESCRIPTION (Scanned from the applicant's description): This program seeks to develop a transdermal system capable of delivering 1,500 ug of levonorgestrel over the course of 24 hours through two 30 cm2 patches. Such a system should be as effective for emergency contraception as… More

Transdermal Levonorgestrel for Emergency Contraception

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $0.00
Abstract:
DESCRIPTION (Scanned from the applicant's description): This program seeks to develop a transdermal system capable of delivering 1,500 ug of levonorgestrel over the course of 24 hours through two 30 cm2 patches. Such a system should be as effective for emergency contraception as… More

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: E. S. Nuwayser
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: E. S. Nuwayser
Award Amount: $377,920.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: E. Nuwayser
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator: E. Nuwayser
Award Amount: $548,536.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $547,931.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2001 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $713,367.00

A 30-DAY INJECTION FOR TREATMENT OF URINARY INCONTINENCE

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $99,956.00
Abstract:
DESCRIPTION (Verbatim from the Applicant's Abstract): The involuntary loss of urine while awake or asleep is a malodorous social stigma, commonly concealed by its embarrassed victim with a mountain of absorbent pads. An estimated l 0 million Americans are incontinent, at a cost… More

TRANSDERMAL BUPRENORPHINE FOR OPIATE ANTAGONIST THERAPY

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $99,876.00
Abstract:
DESCRIPTION (provided by applicant): Opiate antagonist therapy is an important treatment for recently withdrawn narcotic addicts. Buprenorphine is a drug with mixed agonist-antagonist properties, which eliminates physiological reinforcement by preventing any subjective reward from morphine-like… More

BUPRENORPHINE MICROCAPSULES FOR HEROIN ADDICTION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Elie S. Nuwayser
Award Amount: $99,965.00
Abstract:
DESCRIPTION (provided by applicant): The overall objective of the program is to develop a new more economical sustained action injectable formulation of -buprenorphine, based on microcapsules prepared by BIOTEK's air suspension process. The microcapsules will be used in a… More

INNOVATIVE SINGLE-DOSE HEPATITIS B VACCINE FORMULATION

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: J. P. Kitchell
Award Amount: $96,565.00
Abstract:
DESCRIPTION (provided by applicant): Hepatitis B (HBV) is a serious viral disease that can result in acute massive hepatic necrosis, chronic active hepatitis, and cirrhosis of the liver. HBV vaccines are commercially available and HBV vaccination is now recommended for all infants, adolescents,… More

A ONE YEAR ESTROGEN/PROGESTIN IMPLANT

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $0.00
Abstract:
This program targets a one-year biodegradable estrogen/progestin implant for postmenopausal hormone replacement therapy. Estradiol plus levonorgestrel will be incorporated into an innovative implant design already being developed by BIOTEK for delivery of pure levonorgestrel as a maintenance… More

A ONE YEAR ESTROGEN/PROGESTIN IMPLANT

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $744,898.00
Abstract:
This program targets a one-year biodegradable estrogen/progestin implant for postmenopausal hormone replacement therapy. Estradiol plus levonorgestrel will be incorporated into an innovative implant design already being developed by BIOTEK for delivery of pure levonorgestrel as a maintenance… More

A NEW METHOD FOR TREATING SLEEP DISORDERS

Award Year / Program / Phase: 2002 / SBIR / Phase II
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $494,477.00
Abstract:
DESCRIPTION (provided by applicant): BIOTEK has developed a transdermal melatonin formulation capable of producing flux levels high enough to allow a small patch to deliver a night-time melatonin pulse similar to that of healthy young adults. Such delivery should foster drowsiness, restful sleep,… More

A NEW METHOD FOR TREATING SLEEP DISORDERS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: L. D. Nichols
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): BIOTEK has developed a transdermal melatonin formulation capable of producing flux levels high enough to allow a small patch to deliver a night-time melatonin pulse similar to that of healthy young adults. Such delivery should foster drowsiness, restful sleep,… More

Microlayered Erythropoietin Implants

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: J. P. Kitchell
Award Amount: $99,975.00
Abstract:
DESCRIPTION (provided by applicant): BIOTEK has discovered a unique processing method for the efficient and safe formulation of peptides or proteins in polylactide-co-glycolide (PLGA) polymer for long-term implantable delivery. The process is very mild, it gives high yield, and residual organic… More

Vaginal Bioprotection by Controlled Acidification

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $861,833.00
Abstract:
DESCRIPTION (provided by applicant): A single unobtrusive product capable of protecting women against both disease and pregnancy should gain widespread acceptance. BIOTEK is investigating a new vaginal gel, which deactivates pathogens by low pH buffering. Phase I developed and studied vaginal gels… More

Transdermal Buprenorphine for Opiate Antagonist Therapy

Award Year / Program / Phase: 2004 / SBIR / Phase II
Agency: HHS
Principal Investigator: Larry D. Nichols
Award Amount: $765,206.00
Abstract:
DESCRIPTION (provided by applicant): Opiate antagonist therapy is an important treatment for recently withdrawn opiate addicts. Buprenorphine is a mixed agonist-antagonist which eliminates physiological reinforcement by blocking subjective opiate reward. Recently marketed as sublingual tablets,… More